ABO-incompatible pediatric lung transplant performed with immunoadsorption column system: A case report Authors: Alilis Fontana Bellorín, Alejandro Vázquez Sánchez, Verónica Monfort Drago, Richard Issitt, Pablo Álvarez, Carlos Jordá Aragón, Gabriel Sales Badía Published: 2026 A 4-year-old lung donor for a 11-month-old patient. Central Message Intraoperative immunoadsorption enabled successful ABOi lobar lung transplantation in an infant on central ECMO, achieving sustained ABO tolerance over 23 months of follow-up. An 11-month-old infant was admitted to the intensive care unit after cardiorespiratory arrest associated with the parainfluenza virus. Despite interventions, deterioration persisted. Echocardiography revealed severe pulmonary hypertension, tricuspid gradient >100 mm Hg, and right ventricular dilation. Maximal vasodilator therapy failed. At 72 hours, cardiogenic shock led to carotid-jugular venoarterial extracorporeal membrane oxygenation (ECMO). Unsuccessful weaning by day 22 prompted the consideration of a lung transplant. During this time, ECMO arterial cannula clotting occurred, requiring sternotomy for atrial-aortic ECMO (Figure 1, A). A, Transplant-bridge ECMO system with Berlin Heart cannula and pericardium covering with Gore-Tex patch (W. L. Gore & Associates, Inc). B, Pneumonectomy of the native lung. C, Bench surgery of the donor's lungs. D, Bicaval cannulation for venous-arterial ECMO. ECMO, Extracorporeal membrane oxygenation. Given the scarcity of donors, an ABO-incompatible (ABOi) strategy (the GOSH protocol)1 was adopted. On day 42, a 4-year-old donor, weighing 17 kg and measuring 120 cm in height, with A Rh-blood group was accepted for the B Rh-recipient, who was 12 months old, weighing 6.7 kg, and measuring 62 cm. The donor's middle and inferior right lobes were implanted on the right side, and the inferior left lobe on the left, with size-adapted hilar anastomoses (Figure 1, B and C). Isohemagglutinin (ISO) removal was calculated per the GOSH protocol targeting ≤1:2; initial titers were 1:4. ECMO was converted to bicaval-aortic cardiopulmonary bypass with a secondary arterial line postoxygenator for immunoadsorption (Figure 1, D). This line was linked to a plasmapheresis column and an immunoadsorption column in parallel vertical alignment and then connected to a line returning filtered plasma to the reservoir (Figure 2). Blood from the patient moved through the venous cannula to the oxygenator-heater, returning through the arterial cannula. Some arterial cannula blood was diverted to the plasmapheresis pump (maximum flow 200 mL/min, maximum pressure 100 mm Hg) to isolate the plasma, which flowed through the immunoadsorption column, eliminating ISOs (maximum flow 40 mL/min, maximum pressure 300 mm Hg). “Clean” plasma was then returned to the reservoir and recipient. ISO titers were measured before connecting the circuit, 7 minutes after treatment, after 30 minutes, before reperfusion of the lungs, and before the withdrawal of cardiopulmonary bypass. ISO levels of <1:2 were obtained and maintained. Postoperative ECMO was required as a protective strategy to allow for gradual right ventricular adaptation. Configuration of the cardiopulmonary bypass system with the addition of the plasmapheresis and immunoadsorption column. ISO, Isohemagglutinin. No primary graft dysfunction occurred; ECMO was weaned at 72 hours. Tracheobronchomalacia required tracheostomy; the patient was discharged at 2 months and decannulated at 4 months. At 20 months, graft function was stable with undetectable ISOs. De novo donor-specific antibodies (DSAs) then developed, requiring desensitization. Invasive fungal infection in the context of intensified immunosuppression caused refractory septic shock at 35 months of age; retransplantation was not feasible. ISOs were monitored per protocol and remained undetectable throughout 23 months of follow-up. Pediatric candidates face greater waitlist mortality than adults.2 Intentional ABOi lung transplantation remains rare, with only 2 published cases, to our knowledge.3 Unlike plasma exchange,4 Robertson and colleagues5 introduced intraoperative immunoadsorption to reduce instability and transfusion needs. We applied this protocol for ABOi lung transplantation in an infant on central ECMO, which we chose to minimize immunological risk and ensure hemodynamic stability. The patient's demise resulted from de novo DSA complications, not ABO incompatibility—ISOs remained undetectable throughout, confirming sustained efficacy of immunoadsorption for ABO barrier management. Immunoadsorption is a promising strategy for pediatric ABOi lung transplantation, with sustained ABO tolerance over 23 months. De novo DSA management in pediatric recipients warrants further study. Ethical review and approval were waived for this study because it is a report of a single clinical case. Written informed consent was obtained from the patient's family for the publication of study data. Conflict of Interest Statement The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. References